Luye Pharma Releases its Financial Results for the First Half of 2018: Double-Digit Growth in Core Product Sales, Exceeded Expectations in Sales, R&D and M&As
HONG KONG, Aug. 29, 2018 /PRNewswire/ -- Luye Pharma Group (02186.HK) released its financial results for the first half of 2018 onAugust 26, with the financial report showing the company has maintained strong business performance and double-digit growth in the sale of its established products - s...
2018-08-29 17:40
1326
Luye Pharma Announces the Completion of Acquisition of Acino's Transdermal Drug Delivery Systems Business
HONG KONG, Dec. 1, 2016 /PRNewswire/ -- Luye Pharma Group Ltd. (2186.HK) is pleased to announce the completion of its acquisition of the transdermal drug delivery systems (TDS) business from Swiss company, Acino. The acquired business is a global leader in niche transdermal markets and will great...
2016-12-01 17:18
2501
